Drug intelligence / Profile preview

ALM201

Development stage: Unknown
Lead developer: Almac Discovery
Modality: Peptides
Administration: Subcutaneous

Overview

ALM201 is a synthetic peptide derived from the FKBPL protein, acting as an anti-angiogenic agent. It is being investigated for its potential in treating various cancers, including ovarian cancer. Developed by Almac Discovery, it has been granted Orphan Drug Designation for ovarian cancer.

Other names: FKBPL-derived anticancer peptidesPeptide anti-angiogenic compounds

Targets

CD44 (CD44 antigen)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ALM201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM201.

Explore the full profile